Advances in respiratory virus therapeutics - A meeting report from the 6th for isirv Antiviral Group conference
Advances in respiratory virus therapeutics - A meeting report from the 6th for isirv Antiviral Group conference
复制标题
DOI：
10.1016/j.antiviral.2019.04.006
复制
发表时间：
2019-07-01
影响因子：
7.6
通讯作者：
Sims, Amy C.
中科院分区：
文献类型：
--
作者：
Beigel, John H.;Nam, Hannah H.;Sims, Amy C.
国际流感和其他呼吸道病毒疾病学会于2018年11月13日至15日在马里兰州罗克维尔举行了第六届抗病毒小组（isirv-AVG）会议。为期三天的项目重点是针对季节性和大流行性流感、呼吸道合胞病毒、冠状病毒（包括MERS-CoV和SARS-CoV）、人鼻病毒和其他呼吸道病毒的治疗。介绍了几种流感抗病毒药物的更新，包括baloxavir、CC-42344、VIS 410、免疫球蛋白、免疫血浆、MHAA 4549 A、pimodivir（JNJ-63623872）、乌非诺韦和HA迷你粘合剂; RSV抗病毒药物，包括presatovir（GS-5806）、ziresovir（AK 0529）、lumicitabine（ALS-008176）、JNJ-53718678、JNJ-64417184和EDP-938;广谱抗病毒药，如法匹拉韦、VH 244、remdesivir和EIDD-1931/EIDD-2801;和宿主导向策略，包括硝唑尼特、艾立托仑和地尔硫卓。其他主题包括新终点的考虑，如顺序量表和患者报告结局（PRO），研究设计问题，以及抗病毒药物开发的其他监管考虑。本报告的目的是提供这次会议上所作发言的摘要。
The International Society for Influenza and other Respiratory Virus Diseases held its 6th Antiviral Group (isirv-AVG) conference in Rockville, Maryland, November 13-15, 2018. The three-day program was focused on therapeutics towards seasonal and pandemic influenza, respiratory syncytial virus, coronaviruses including MERS-CoV and SARS-CoV, human rhinovirus, and other respiratory viruses. Updates were presented on several influenza antivirals including baloxavir, CC-42344, VIS410, immunoglobulin, immune plasma, MHAA4549A, pimodivir (JNJ-63623872), umifenovir, and HA minibinders; RSV antivirals including presatovir (GS-5806), ziresovir (AK0529), lumicitabine (ALS-008176), JNJ-53718678, JNJ-64417184, and EDP-938; broad spectrum antivirals such as favipiravir, VH244, remdesivir, and EIDD-1931/EIDD-2801; and host directed strategies including nitazoxanide, eritoran, and diltiazem. Other topics included considerations of novel endpoints such as ordinal scales and patient reported outcomes (PRO), and study design issues, and other regulatory considerations for antiviral drug development. The aim of this report is to provide a summary of the presentations given at this meeting.